Metagenomic analyses of the gut microbiota associated with colorectal adenoma/Experiment 1

From BugSigDB


Reviewed Marked as Reviewed by Atrayees on 2023-7-20

Curated date: 2022/07/04

Curator: Jeshudy

Revision editor(s): Jeshudy, LGeistlinger, Peace Sandy

Subjects

Location of subjects
Japan
Host species Species from which microbiome was sampled. Contact us to have more species added.
Homo sapiens
Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
Intestine Bowel,Intestinal tract,Intestine,intestine
Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
Colorectal cancer cancer of colorectum,cancer of large bowel,cancer of large intestine,cancer of the large bowel,colon cancer,colorectal cancer,colorectum cancer,CRC,large intestine cancer,malignant colorectal neoplasm,malignant colorectal tumor,malignant colorectum neoplasm,malignant large bowel neoplasm,malignant large bowel tumor,malignant large intestine neoplasm,malignant large intestine tumor,malignant neoplasm of colorectum,malignant neoplasm of large bowel,malignant neoplasm of large intestine,malignant neoplasm of the large bowel,malignant neoplasm of the large intestine,malignant tumor of large bowel,malignant tumor of large intestine,malignant tumor of the large bowel,malignant tumor of the large intestine,Colorectal cancer
Group 0 name Corresponds to the control (unexposed) group for case-control studies
Healthy
Group 1 name Corresponds to the case (exposed) group for case-control studies
Intramucosal CRC
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
Intramucosal CRC is in its earliest stage (stage 0) and is also known as carcinoma in situ or intramucosal carcinoma. Intramucosal CRC has not yet grown beyond the inner mucosal layer of the colorectum
Group 0 sample size Number of subjects in the control (unexposed) group
10
Group 1 sample size Number of subjects in the case (exposed) group
24
Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
None Specified

Lab analysis

Sequencing type
16S
16S variable region One or more hypervariable region(s) of the bacterial 16S gene
V3-V4
Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
Illumina

Statistical Analysis

Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
relative abundances
Statistical test
LEfSe
Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
0.05
LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
3

Alpha Diversity

Shannon Estimator of species richness and species evenness: more weight on species richness
unchanged

Signature 1

Reviewed Marked as Reviewed by Atrayees on 2023-7-20

Curated date: 2022/07/04

Curator: Jeshudy

Revision editor(s): Jeshudy, Atrayees

Source: Figure 4B, Figure 7

Description: Characterization of microbiomes in intramucosal CRC patients and healthy subjects.

Abundance in Group 1: decreased abundance in Intramucosal CRC

NCBI Quality ControlLinks
Megamonas
Sphingobium
Fusobacterium periodonticum
Fusobacterium perfoetens

Revision editor(s): Jeshudy, Atrayees

Signature 2

Reviewed Marked as Reviewed by Atrayees on 2023-7-20

Curated date: 2022/07/04

Curator: Jeshudy

Revision editor(s): Jeshudy, Atrayees

Source: Figure 4B, Figure 7

Description: Characterization of microbiomes in intramucosal CRC patients and healthy subjects.

Abundance in Group 1: increased abundance in Intramucosal CRC

NCBI Quality ControlLinks
Actinobacillus
Fusobacterium
Parvimonas
Peptostreptococcus
Actinomyces
Fusobacteriia
Fusobacteriales
Fusobacteriaceae
Fusobacterium varium

Revision editor(s): Jeshudy, Atrayees